Privia Health Group Inc
NASDAQ: PRVA · HEALTHCARE · HEALTH INFORMATION SERVICES
Updated 2026-04-29
Privia Health Group Inc (PRVA) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for PRVA.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
PRVA historical valuation range
Where current P/E sits in PRVA's own 5Y range.
PRVA intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
PRVA valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 137.17x
P/S Ratio — History
Current: 1.46x
Is PRVA overvalued in 2026?
Privia Health Group Inc (PRVA) currently trades at $24.69 per share with a market capitalization of $3,101,681,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 48/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 137.2x, above its 5-year median of 132.9x.
Looking at its own history, PRVA is currently trading more expensive than 63% of the last 5Y on P/E. This places it in the 63th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates PRVA's intrinsic value at $72.49 per share, against the current market price of $24.69. This implies a margin of safety of +70.20%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: PRVA appears richly valued on our framework, with a Smart Value Score of 48/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is PRVA overvalued in 2026?
Based on a Smart Value Score of 48/100, PRVA appears overvalued. Current price exceeds what fundamentals currently justify.
What is PRVA's fair value?
Our DCF model estimates PRVA's intrinsic value at $72.49 per share, versus the current price of $24.69. This produces a margin of safety of +70.20%.
What P/E ratio does PRVA trade at?
PRVA trades at a P/E of 137.2x on trailing twelve-month earnings, compared to its 5-year median of 132.9x.
Is PRVA a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 48/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does PRVA's valuation compare to its history?
On P/E, PRVA currently sits in the 63th percentile of its own 5Y range. That is above its long-run median relative to where it has traded over the period.
What is PRVA's Smart Value Score?
PRVA's Smart Value Score is 48/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.